A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Clinical trial NCT05108766 · COMPLETED

Trial details

NCT number: NCT05108766
Sponsor: Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Plaque Psoriasis

Start date: 2020-12-17
Primary completion: 2021-06-07
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.